News

New PMPRB Report examines most promising medicines currently in clinical trials worldwide

May 30, 2019

The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the 2018 edition of Meds Pipeline Monitor.


New Drug Landscape Dominated by High-cost Medicines

February 19, 2019

The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the 2017 edition of Meds Entry Watch, an annual publication that provides the latest information on new medicines entering Canadian and international markets.


Patented Medicine Prices Review Board issues a Notice of Hearing for allegations of excessive pricing of Procysbi

January 16, 2019

The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine cysteamine bitartrate, sold under the trade name “Procysbi” by the patentee Horizon Therapeutics Canada.


Canadian per capita use and spending on drugs for chronic retinal diseases among the highest in the OECD

December 12, 2018

Spending on drug class grew by 16.7% in 2017 and stands at just under $700 million


Patented Medicine Prices Review Board seeks applicants for Vice-Chairperson and Board member positions

December 5, 2018

Governor in Council selection processes underway


PAGE 1 - 2 - 3 - 4 - 5  NEXT 25  LAST 5 
Date modified: